KOL List Validation and Prioritisation in Pharma & Biotech
KOL list validation and prioritisation ensures your expert strategy is built on accurate, up‑to‑date and defensible information rather than legacy spreadsheets and anecdotal knowledge. Over time, KOL lists can become bloated, inconsistent and misaligned with current brand priorities; some experts remain on the list because they always have been, while new, influential voices are missing. A structured KOL list validation and prioritisation service helps pharma and biotech teams clean, refine and re‑focus their KOL universe so every interaction, advisory board and engagement plan is targeted where it will make the greatest impact.
Why KOL list validation is essential
KOL lists are often created over years by different teams, affiliates and agencies, using varying criteria and formats. Without validation, this can lead to:
- Duplicated or outdated contacts that no longer reflect current roles or influence
- Imbalanced lists that over‑represent some specialties, centres or countries and under‑represent others
- Hidden gaps where key trialists, guideline contributors, digital voices or catalysts of change are missing
- Difficulty explaining why certain experts are considered “top KOLs” from a compliance or governance perspective
KOL list validation addresses these issues by systematically checking who is on your list, why they are there and whether they still align with your strategic needs.
How we validate your existing KOL lists
Our KOL List Validation and Prioritisation service is designed to work with what you already have, not start again from zero:
- Consolidating and standardising your data
We bring together existing lists from global, regional and local teams, standardising fields, removing duplicates and creating a single view of each expert across sources. - Checking status and relevance
We confirm current roles, affiliations and scientific activity, and assess whether each KOL still matches your disease focus, lifecycle stage and strategic priorities. - Enriching with external indicators
Where needed, we layer in external signals such as publications, trial involvement, congress participation, guideline contributions or digital activity to provide an objective view of current influence. - Incorporating internal insight
Input from medical, commercial, field and local teams is used to validate practical influence in practice, clarify historic relationships and highlight experts who may be under‑ or over‑valued.
This process gives you a cleaner, more accurate baseline KOL universe that reflects today’s reality rather than past assumptions.
Prioritising KOLs for real decisions
Once your list is validated, we focus on prioritisation – answering the question: “Who matters most for what we are trying to achieve now?”
- Defining clear prioritisation criteria
Together, we agree which factors should drive priority for your current strategy, such as scientific leadership, practice influence, digital reach, geographic relevance, access to target populations or experience with specific mechanisms. - Building transparent scoring and segments
We apply these criteria consistently across the list, creating clear tiers and segments (for example: Priority 1 strategic leaders, Priority 2 key collaborators, Priority 3 emerging experts) that can be easily explained to stakeholders and auditors. - Aligning priorities with use cases
We link segments to use cases such as advisory roles, clinical collaboration, education, evidence generation or local pathway change, so your teams can see which experts to approach for which type of activity.
The outcome is a ranked, segmented KOL universe that is straightforward to use in planning, budgeting and engagement.
What KOL list validation and prioritisation delivers
A completed validation and prioritisation project provides:
- A single, de‑duplicated and updated KOL master list across markets and teams
- Clear visibility of which experts are truly high priority and which should move down or off the list
- Identification of gaps where new KOL identification or emerging expert work is needed
- Transparent, documented criteria that support compliance, governance and internal alignment
- Practical guidance on how to use each segment across medical, commercial and clinical activities
This gives your organisation a stronger foundation for expert engagement, reduces wasted effort and improves confidence that your KOL strategy is both effective and defensible.
Integrating validation into ongoing KOL management
KOL list validation and prioritisation should not be a one‑off exercise. We can help you embed periodic review cycles, simple update processes and clear ownership so your lists evolve with your therapy areas, pipelines and markets. When combined with ongoing KOL identification, mapping and DOL work, this creates a living, strategic expert ecosystem where you always know who your most important partners are – and why.
Speak to us about how we can
help you identify the people who can most strongly impact the success of your brand and evidence strategy.